226950 — OliX Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩321bn
- KR₩345bn
- KR₩17bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 35,540 | 68,111 | 49,757 | 61,872 | 25,925 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 541 | 518 | 552 | 1,147 | 5,283 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 37,440 | 69,047 | 52,240 | 65,046 | 32,142 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,911 | 6,180 | 31,525 | 37,232 | 43,910 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 45,207 | 78,577 | 86,672 | 132,651 | 102,825 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,754 | 4,488 | 40,365 | 39,543 | 6,563 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,409 | 33,292 | 68,151 | 66,744 | 52,971 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 41,798 | 45,286 | 18,521 | 65,907 | 49,855 |
Total Liabilities & Shareholders' Equity | 45,207 | 78,577 | 86,672 | 132,651 | 102,825 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |